Early Loop Diuretic Tx Tied to Lower Mortality in Heart Failure

Share this content:
Early Loop Diuretic Tx Tied to Lower Mortality in Heart Failure
Early Loop Diuretic Tx Tied to Lower Mortality in Heart Failure

WEDNESDAY, June 21, 2017 (HealthDay News) -- For patients with acute heart failure, early treatment with loop diuretics is associated with lower in-hospital mortality, according to a study published online June 19 in the Journal of the American College of Cardiology.

Yuya Matsue, M.D., Ph.D., from Kameda Medical Center in Japan, and colleagues conducted a prospective multicenter observational cohort study involving patients with acute heart failure admitted through the emergency department. The authors examined the correlation between time to diuretic treatment (door-to-furosemide [D2F] time) and clinical outcome.

The researchers found that the median D2F time was 90 minutes among the 1,291 patients treated with intravenous furosemide within 24 hours of emergency department arrival; 37.3 percent of patients were classified as the early-treatment group (D2F time of <60 minutes). Compared with the non-early-treatment group, these patients were more likely to arrive by ambulance and had more signs of congestion. The early-treatment group had significantly lower in-hospital mortality (2.3 versus 6.0 percent). Earlier treatment remained significantly correlated with lower in-hospital mortality in multivariate analysis (odds ratio, 0.39).

"In this prospective multicenter, observational cohort study of patients presenting at the emergency department for acute heart failure, early treatment with intravenous loop diuretics was associated with lower in-hospital mortality," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »